The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia.
Eunice S. Wang
No relevant relationships to disclose
Gerald J. Fetterly
No relevant relationships to disclose
Laura Pitzonka
No relevant relationships to disclose
William E. Brady
No relevant relationships to disclose
Wei Tan
No relevant relationships to disclose
Jessica Greene
No relevant relationships to disclose
Deborah Munster
No relevant relationships to disclose
Carlos Vigil
No relevant relationships to disclose
Jason Harold Mendler
No relevant relationships to disclose
Michael W Becker
No relevant relationships to disclose
Kristen Marie Carr-O'Dwyer
No relevant relationships to disclose
Meir Wetzler
No relevant relationships to disclose
Jane Liesveld
No relevant relationships to disclose